Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $69 | $77 | $76 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Cost of Goods Sold | $0 | $32 | $31 | $34 |
| Gross Profit | $0 | $37 | $46 | $42 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| R&D Expenses | $0 | $6 | $7 | $6 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $0 | $21 | $23 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $17 | $0 |
| Other Operating Expenses | $0 | $2 | $6 | $2 |
| Operating Expenses | $0 | $30 | $36 | $30 |
| Operating Income | $0 | $8 | $10 | $12 |
| % Margin | 14.9% | 11% | 12.8% | 15.4% |
| Other Income/Exp. Net | -$0 | -$0 | $2 | -$0 |
| Pre-Tax Income | $0 | $7 | $12 | $11 |
| Tax Expense | $0 | $2 | $4 | $3 |
| Net Income | $0 | $6 | $9 | $9 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS | 0.17 | 17.33 | 25.74 | 25.32 |
| % Growth | -99% | -32.7% | 1.7% | – |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $4 | $4 | $5 |
| EBITDA | $0 | $12 | $18 | $16 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |